vs
Side-by-side financial comparison of Nutex Health, Inc. (NUTX) and OPKO HEALTH, INC. (OPK). Click either name above to swap in a different company.
Nutex Health, Inc. is the larger business by last-quarter revenue ($151.7M vs $148.5M, roughly 1.0× OPKO HEALTH, INC.). Nutex Health, Inc. runs the higher net margin — 7.8% vs -21.1%, a 28.9% gap on every dollar of revenue. On growth, OPKO HEALTH, INC. posted the faster year-over-year revenue change (-19.2% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $-28.6M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs -7.5%).
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
OPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".
NUTX vs OPK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $151.7M | $148.5M |
| Net Profit | $11.8M | $-31.3M |
| Gross Margin | 30.4% | 43.1% |
| Operating Margin | 20.4% | -25.8% |
| Net Margin | 7.8% | -21.1% |
| Revenue YoY | -41.1% | -19.2% |
| Net Profit YoY | -80.8% | -322.8% |
| EPS (diluted) | $2.34 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $151.7M | $148.5M | ||
| Q3 25 | $267.8M | $151.7M | ||
| Q2 25 | $244.0M | $156.8M | ||
| Q1 25 | $211.8M | $150.0M | ||
| Q4 24 | $257.6M | $183.6M | ||
| Q3 24 | $78.8M | $173.6M | ||
| Q2 24 | $76.1M | $182.2M | ||
| Q1 24 | $67.5M | $173.7M |
| Q4 25 | $11.8M | $-31.3M | ||
| Q3 25 | $55.4M | $21.6M | ||
| Q2 25 | $-17.7M | $-148.4M | ||
| Q1 25 | $21.2M | $-67.6M | ||
| Q4 24 | $61.6M | $14.0M | ||
| Q3 24 | $-8.8M | $24.9M | ||
| Q2 24 | $-364.0K | $-10.3M | ||
| Q1 24 | $-364.0K | $-81.8M |
| Q4 25 | 30.4% | 43.1% | ||
| Q3 25 | 57.8% | 32.9% | ||
| Q2 25 | 51.2% | 31.5% | ||
| Q1 25 | 55.9% | 28.4% | ||
| Q4 24 | 55.0% | 46.1% | ||
| Q3 24 | 27.8% | 23.1% | ||
| Q2 24 | 29.7% | 28.4% | ||
| Q1 24 | 15.1% | 24.2% |
| Q4 25 | 20.4% | -25.8% | ||
| Q3 25 | 48.7% | 31.7% | ||
| Q2 25 | 13.8% | -38.3% | ||
| Q1 25 | 38.1% | -44.8% | ||
| Q4 24 | 44.4% | -18.0% | ||
| Q3 24 | 12.3% | 8.2% | ||
| Q2 24 | 7.0% | -33.9% | ||
| Q1 24 | 2.1% | -41.2% |
| Q4 25 | 7.8% | -21.1% | ||
| Q3 25 | 20.7% | 14.3% | ||
| Q2 25 | -7.3% | -94.7% | ||
| Q1 25 | 10.0% | -45.1% | ||
| Q4 24 | 23.9% | 7.6% | ||
| Q3 24 | -11.2% | 14.3% | ||
| Q2 24 | -0.5% | -5.7% | ||
| Q1 24 | -0.5% | -47.1% |
| Q4 25 | $2.34 | $-0.04 | ||
| Q3 25 | $7.76 | $0.03 | ||
| Q2 25 | $-2.95 | $-0.19 | ||
| Q1 25 | $3.33 | $-0.10 | ||
| Q4 24 | $11.56 | $0.02 | ||
| Q3 24 | $-1.72 | $0.03 | ||
| Q2 24 | $-0.07 | $-0.01 | ||
| Q1 24 | $-0.08 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $185.6M | $364.4M |
| Total DebtLower is stronger | — | $344.0M |
| Stockholders' EquityBook value | $329.4M | $1.3B |
| Total Assets | $918.5M | $1.9B |
| Debt / EquityLower = less leverage | — | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $185.6M | $364.4M | ||
| Q3 25 | $166.0M | $412.0M | ||
| Q2 25 | $96.7M | $267.3M | ||
| Q1 25 | $84.7M | $428.8M | ||
| Q4 24 | $40.6M | $426.6M | ||
| Q3 24 | $46.9M | $400.1M | ||
| Q2 24 | $40.8M | $40.6M | ||
| Q1 24 | $30.0M | $75.6M |
| Q4 25 | — | $344.0M | ||
| Q3 25 | — | $344.2M | ||
| Q2 25 | — | $343.3M | ||
| Q1 25 | — | $439.2M | ||
| Q4 24 | — | $437.2M | ||
| Q3 24 | — | $441.0M | ||
| Q2 24 | — | $201.9M | ||
| Q1 24 | — | $350.1M |
| Q4 25 | $329.4M | $1.3B | ||
| Q3 25 | $317.2M | $1.3B | ||
| Q2 25 | $235.3M | $1.3B | ||
| Q1 25 | $176.9M | $1.3B | ||
| Q4 24 | $132.4M | $1.4B | ||
| Q3 24 | $60.4M | $1.4B | ||
| Q2 24 | $62.7M | $1.4B | ||
| Q1 24 | $63.0M | $1.3B |
| Q4 25 | $918.5M | $1.9B | ||
| Q3 25 | $964.5M | $2.0B | ||
| Q2 25 | $841.0M | $2.0B | ||
| Q1 25 | $761.9M | $2.1B | ||
| Q4 24 | $655.3M | $2.2B | ||
| Q3 24 | $438.5M | $2.3B | ||
| Q2 24 | $422.4M | $2.0B | ||
| Q1 24 | $404.3M | $2.0B |
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.33× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.31× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.4M | $-25.9M |
| Free Cash FlowOCF − Capex | $69.0M | $-28.6M |
| FCF MarginFCF / Revenue | 45.5% | -19.3% |
| Capex IntensityCapex / Revenue | 0.9% | 1.8% |
| Cash ConversionOCF / Net Profit | 5.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | $245.6M | $-190.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.4M | $-25.9M | ||
| Q3 25 | $99.5M | $-34.6M | ||
| Q2 25 | $27.3M | $-83.4M | ||
| Q1 25 | $51.0M | $-34.6M | ||
| Q4 24 | $54.0K | $-44.4M | ||
| Q3 24 | $6.8M | $-77.1M | ||
| Q2 24 | $13.3M | $-26.4M | ||
| Q1 24 | $3.1M | $-35.6M |
| Q4 25 | $69.0M | $-28.6M | ||
| Q3 25 | $99.2M | $-37.8M | ||
| Q2 25 | $26.5M | $-86.7M | ||
| Q1 25 | $50.9M | $-37.7M | ||
| Q4 24 | $-341.0K | $-49.8M | ||
| Q3 24 | $6.2M | $-85.0M | ||
| Q2 24 | $12.7M | $-33.7M | ||
| Q1 24 | $2.3M | $-40.0M |
| Q4 25 | 45.5% | -19.3% | ||
| Q3 25 | 37.0% | -24.9% | ||
| Q2 25 | 10.9% | -55.3% | ||
| Q1 25 | 24.0% | -25.2% | ||
| Q4 24 | -0.1% | -27.1% | ||
| Q3 24 | 7.8% | -49.0% | ||
| Q2 24 | 16.7% | -18.5% | ||
| Q1 24 | 3.4% | -23.0% |
| Q4 25 | 0.9% | 1.8% | ||
| Q3 25 | 0.1% | 2.1% | ||
| Q2 25 | 0.3% | 2.1% | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.2% | 2.9% | ||
| Q3 24 | 0.8% | 4.6% | ||
| Q2 24 | 0.7% | 4.0% | ||
| Q1 24 | 1.1% | 2.6% |
| Q4 25 | 5.95× | — | ||
| Q3 25 | 1.80× | -1.60× | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.40× | — | ||
| Q4 24 | 0.00× | -3.17× | ||
| Q3 24 | — | -3.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
OPK
| Services | $71.1M | 48% |
| Transfer Of Intellectual Property And Other | $33.7M | 23% |
| IE | $22.1M | 15% |
| Rayaldee | $8.8M | 6% |
| Barda Agreement | $6.8M | 5% |
| MX | $6.3M | 4% |
